Aditxt, Inc. announced the formation of a U.S.-based subsidiary Adimune, Inc. (Adimune) and its plans towards submission of a Clinical Trial Application (CTA) for its immunotherapeutic technology drug candidate, ADI-100 (ADI-100” or ADI). The CTA application will request approval for Adimune to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023. A second study is also planned for type 1 diabetes.